Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...

The GnRH inhibitor market is shifting toward more convenient, patient-focused treatments, driven by oral therapies such as ORGOVYX and YSELTY. As the pipeline continues to grow and indications expand, ...

May 11, 2011 — Gonadotropin-releasing hormone (GnRH) antagonists give similar live-birth rates as GnRH agonists but with markedly lower incidence of severe ovarian hyperstimulation syndrome (OHSS), ...

Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials. 10-Year efficacy and co-morbidity outcomes of a ...

Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule ...

NEW ORLEANS -- Off-label use of oral elagolix (Orilissa) may be a more patient-friendly alternative to standard-of-care injectable GnRH antagonists for ovulation suppression during in vitro ...

Abstract: Immunocontraceptive vaccines based on gonadotropin-releasing hormone (GnRH) have been tested in adult white-tailed deer (Odocoileus virginianus), but their effects on fawns are unknown. The ...